Geneos Therapeutics, Inc.
Geneos Therapeutics is a clinical stage biotherapeutics company dedicated to developing personalized therapeutic cancer vaccines (PTCVs) using its proprietary GT-EPIC™ platform. The company aims to bring a new immunotherapeutic paradigm for cancer treatment by creating custom vaccines that include up to 40 neoantigens unique to each patient's tumor. Their approach involves rapid manufacturing and delivery of these personalized vaccines, which stimulate the immune system to target and eradicate cancer cells. With a focus on hepatocellular carcinoma and other cancers, Geneos is advancing clinical trials and exploring the potential of neoantigen-targeted immunotherapies to transform cancer care.
Industries
Nr. of Employees
small (1-50)
Geneos Therapeutics, Inc.
Plymouth Meeting, Pennsylvania, United States, North America
Products
Personalized therapeutic cancer vaccine (DNA plasmid-based PTCV)
Patient-specific DNA plasmid vaccine encoding a multi-neoantigen insert (up to ~40 neoantigens per plasmid) administered intradermally with a plasmid-encoded IL-12 adjuvant and delivered using in vivo electroporation to induce neoantigen-specific CD4+ and CD8+ T cell responses.
Personalized therapeutic cancer vaccine (DNA plasmid-based PTCV)
Patient-specific DNA plasmid vaccine encoding a multi-neoantigen insert (up to ~40 neoantigens per plasmid) administered intradermally with a plasmid-encoded IL-12 adjuvant and delivered using in vivo electroporation to induce neoantigen-specific CD4+ and CD8+ T cell responses.
Services
Personalized vaccine design and manufacture (biopsy-to-treatment)
End-to-end service that sequences tumor tissue, identifies neoantigens, designs patient-specific DNA plasmid vaccine constructs (including plasmid-encoded IL-12), and manages GMP manufacture and delivery for clinical use with accelerated turnaround timelines.
Clinical development and immunomonitoring services for personalized oncology vaccines
Design and implementation of early-phase clinical trials (including investigator-sponsored and single-arm Phase 1b/2a studies), serial biopsy collection, immunomonitoring (ELISpot, flow cytometry, TCR sequencing, single-cell analysis) and longitudinal ctDNA biomarker integration.
Personalized vaccine design and manufacture (biopsy-to-treatment)
End-to-end service that sequences tumor tissue, identifies neoantigens, designs patient-specific DNA plasmid vaccine constructs (including plasmid-encoded IL-12), and manages GMP manufacture and delivery for clinical use with accelerated turnaround timelines.
Clinical development and immunomonitoring services for personalized oncology vaccines
Design and implementation of early-phase clinical trials (including investigator-sponsored and single-arm Phase 1b/2a studies), serial biopsy collection, immunomonitoring (ELISpot, flow cytometry, TCR sequencing, single-cell analysis) and longitudinal ctDNA biomarker integration.
Expertise Areas
- Personalized cancer vaccine development
- Neoantigen discovery and computational pipeline for target selection
- DNA plasmid vaccine engineering and delivery
- Early-phase oncology clinical trial design and execution
Key Technologies
- Exome and transcriptome sequencing
- Personalized DNA plasmid vaccine platforms
- In vivo electroporation-mediated intradermal delivery
- Plasmid-encoded cytokine adjuvants (IL-12)